MorphoSys Valuation

Is MOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MOR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MOR's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOR?

Other financial metrics that can be useful for relative valuation.

MOR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue8.8x
Enterprise Value/EBITDA-8.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MOR's PS Ratio compare to its peers?

The above table shows the PS ratio for MOR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.7x
BIO3 Biotest
1.6x6.3%€1.4b
FYB Formycon
10.8x24.8%€743.4m
HPHA Heidelberg Pharma
8.5x-6.2%€143.1m
MDG1 Medigene
5.8x15.6%€52.1m
MOR MorphoSys
10.6x21.9%€2.5b

Price-To-Sales vs Peers: MOR is expensive based on its Price-To-Sales Ratio (10.6x) compared to the peer average (6.7x).


Price to Earnings Ratio vs Industry

How does MOR's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.1%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.1%
n/an/an/a
No more companies

Price-To-Sales vs Industry: MOR is expensive based on its Price-To-Sales Ratio (10.6x) compared to the European Biotechs industry average (10.5x).


Price to Sales Ratio vs Fair Ratio

What is MOR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.6x
Fair PS Ratio4.3x

Price-To-Sales vs Fair Ratio: MOR is expensive based on its Price-To-Sales Ratio (10.6x) compared to the estimated Fair Price-To-Sales Ratio (4.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MOR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€67.20
€58.71
-12.6%
25.3%€68.00€31.00n/a7
Mar ’25€65.50
€50.38
-23.1%
36.4%€68.00€22.00n/a8
Feb ’25€40.62
€31.35
-22.8%
33.5%€47.00€15.00n/a10
Jan ’25€34.00
€31.00
-8.8%
33.6%€47.00€15.00n/a10
Dec ’24€24.44
€31.13
+27.4%
33.3%€47.00€15.00n/a8
Nov ’24€31.29
€34.33
+9.7%
17.8%€45.00€25.00n/a9
Oct ’24€25.83
€31.61
+22.4%
29.1%€45.00€13.50n/a9
Sep ’24€27.89
€27.94
+0.2%
38.9%€45.00€12.50n/a8
Aug ’24€27.00
€28.19
+4.4%
40.0%€47.00€12.50n/a8
Jul ’24€27.23
€25.56
-6.1%
50.9%€47.00€12.50n/a8
Jun ’24€23.80
€23.06
-3.1%
59.3%€47.00€12.00n/a8
May ’24€19.06
€18.31
-3.9%
58.8%€42.00€11.00n/a8
Apr ’24€14.65
€18.31
+25.0%
58.8%€42.00€11.00n/a8
Mar ’24€17.21
€18.25
+6.0%
59.2%€42.00€11.00€65.508
Feb ’24€18.45
€23.44
+27.1%
76.2%€65.00€11.00€40.629
Jan ’24€13.21
€25.06
+89.7%
67.8%€65.00€12.00€34.009
Dec ’23€15.53
€29.11
+87.5%
60.9%€65.00€13.00€24.449
Nov ’23€19.72
€35.61
+80.6%
39.6%€65.00€18.00€31.299
Oct ’23€20.56
€37.17
+80.8%
34.1%€65.00€24.00€25.839
Sep ’23€16.76
€39.85
+137.8%
36.8%€65.00€24.00€27.8910
Aug ’23€22.22
€40.20
+80.9%
36.2%€65.00€24.00€27.0010
Jul ’23€19.40
€40.70
+109.8%
39.3%€72.00€24.00€27.2310
Jun ’23€20.00
€44.33
+121.7%
32.3%€72.00€30.00€23.809
May ’23€20.30
€45.33
+123.3%
30.4%€72.00€30.00€19.069
Apr ’23€24.89
€45.40
+82.4%
29.5%€72.00€30.00€14.6510
Mar ’23€24.25
€61.09
+151.9%
41.9%€124.00€36.00€17.2111

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.